ClinicalTrials.gg
CompletedNCT06096194VD3-eggUpdated Oct 23, 2023

Vitamin D3-enhanced Eggs in Preschool Children

An interventional study of vitamin D-enhanced egg and Control in Vitamin D Deficiency and 25-Hydroxyvitamin D3 Deficiency, Selective, sponsored by Instituto Nacional de Salud Publica, Mexico. Completed at 1 site in Mexico. Open to participants aged 12 Months to 59 Months. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Instituto Nacional de Salud Publica, Mexico · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 1 month after the study started (first participant enrolled Jul 2018, registered Sep 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
12 Months to 59 Months
Sex
All
01

Study summary

This is double-blind, controlled fiel trial, to compare fortified egg with D3-or 25(OH)D3 and non-fortified eggs in healthy preschool-age children 12 to 60 months of age, affiliated to day-care centers at Secretaria de Desarrollo Social (SEDESOL).

The study aims to answer are:

  1. to evaluate the efficacy of fortified egg with vitamian D3 on serum concentrations of 25-hydroxyvitamin D3
  2. and to evaluate parathyroid hormone (PTH) in children aged 12 to 60 months of age.

    • Children would be given for breakfast fortified egg/non-foritfied egg three times per week for 12 weeks.
    • Blood samples will be taken at baseline and at the end of study.
    • Anthropometric meassurements weight /height will be taken at baseline and at end of study.
Read the detailed description
  1. Vitamin D functions:

    Vitamin D (VD) is a fat-soluble vitamin. Its main function is to maintain optimal levels of calcium and phosphorus in the body; it also helps in neuromuscular transmission and bone mineralization, important in bone health and growth in children. There are VD receptors in bone, bone marrow, adipose tissue, adrenal, brain, stomach, small intestine, colon, pancreas, liver, lung, muscle, activated B and T lymphocytes, and in other organs, tissues, and cells. For this reason, various functions are assumed. VD serum concentrations above 75 mmol/l (30 ng/ml) have been shown to keep cell growth under control and prevent cells from becoming autonomous and malignant.

  2. Prevalences of vitamin D deficiencies and insufficiency:

    Worldwide, a high proportion of children, youth, and middle-aged adults are deficient in Vitamin D. It has been estimated that about one billion people in the world may be deficient in Vitamin D.

    In Latin America, only Mexico has representative population data on vitamin D deficiency. Recently it has been documented that the deficiency and insufficiency of Vitamin D are a public health problem in Mexico. In a national representative sample of 6,827 children aged 1 to 11 years who participated in the 2012 National Health and Nutrition Survey (ENSANUT), the prevalence of Vitamin D deficiency was 33% (25-OH-D \<50 nmol/L), which means that there are 3 million children with Vitamin D deficiency in Mexico. On the other hand, insufficiency (25-OH-D of 50 \<75 nmol/L) affects 56% of children. Likewise, it was found that less than 3% of children consume a supplement with Vitamin D.

  3. Vitamin D intake recommendations in children:

    The current vitamin D intake recommendations made by the APP since 2008 (Wagner CL, 2008) for children aged 1 to 8 years is an Adequate Intake of 400-600 IU (10-15µg), and for the Tolerable Upper Intake Level it is suggested do not exceed 2500 IU (63µg) in the case of children from 1 to 3 years and 3000 IU (75µg) in children from 4 to 8 years.

  4. Description of the study:

    A double-blind controlled cluster randomized field trial was developed.

    The participants were children from 6 day-care centers (SEDESOL) at Cuernavaca, Morelos, Mexico. The study sample had 275 children that completed the study (the protocol considered having at least 125 children in each treatment group), from 12 to 59 months, who attended 6 take care centers (SEDESOL), in Cuernavaca, Morelos.

  5. Objective

    To evaluate the efficacy of the consumption of fortified eggs with Vitamin D3 on the serum concentrations of 25-OH-D in children aged 12 to 59 months who attend take care centers (SEDESOL)in Cuernavaca.

  6. Treatment and control groups:

    The random assignments of the intervention group (fortified egg) and control group (unfortified egg) were done considering each day-care center as a unit of allocation.

    Three day-care centers were randomized to the intervention group and three to the control group. The study lasted 12 weeks.

    The treatment group consumed a fortified egg to provide 10 mcg of Vitamin D3 equivalent to 400 IU of Cholecalciferol, 3 times a week.

    The control group received unfortified egg (\~ 43 IU Vitamin D) with the same frequency as the intervention group.

  7. Main Outcomes:

    The main outcome outcome variables were the serum levels of 25-hydroxyvitamin D3 (25-OH-D3) The second main outcome was to evaluate the parathyroid hormone (PTH).

    Other Variables:

    Blood parameters were taken: total cholesterol, HDL cholesterol, triglycerides, glucose, and hemoglobin.

    Anthropometric measurements of weight, height, age.

    Morbidity (diarrhea, constipation and respiratory tract infections) was evaluated three times per week and recorded.

    Standardized personnel weight the egg consumed before and after breakfast with a food weighing scale.

    Mothers were asked about children's usual diet by two diet questionnaires : a 24-hour dietary recall and a food frequency questionnaire at baseline and at the end of the study.

  8. Ethical considerations:

The protocol was submitted to he Research and Ethics Committee of the Medicine Research Division of the National Autonomous University of Mexico.The study was approved on May 8, 2018 with folio FM/DI/028/2018.

The children's mothers or guardians signed an informed consent letter.

02

Conditions studied

  • Vitamin D Deficiency
  • 25-Hydroxyvitamin D3 Deficiency, Selective

Browse trials for

Keywords

  • Vitamin D3
  • enhanced egg
  • Vitamin D3-enhanced egg
  • 25-Hydroxyvitamin D3 Deficiency
  • supplementation
  • Mexico
  • Children
03

In context

Vitamin D Deficiency

801 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

This study's enrollment of 275 is above the median of 78 across 590 interventional studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

Instituto Nacional de Salud Publica, Mexico is the lead sponsor of 31 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of either sex, from 12 to 59 months of age who attend take care SEDESOL centers
  • Children who consume eggs within their usual diet at least 5 times per month
  • Childrens whose parents or legal guardian agree to participate in the study and sign an letter

Exclusion criteria

Exclusion Criteria:

  • Children with an egg allergy
  • Chldren with to vitamin D
  • Children who have taken vitamin D supplements in the past month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    vitamin D3-enhanced egg

    The experimental group consumed an vitamin D3-enhanced egg (\~ 400 IU). The randomization unit was the take care SEDESOL centers. All children in 3 day-care centers were given one vitamin D3-enhanced egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).

    Dietary Supplement: vitamin D-enhanced egg

  • Placebo comparator
    Control

    The control group consumed unfortified egg (\~ 43 IU Vitamin D). The randomization unit was the 6 day-care centers (SEDESOL). All children in 3 day-care centers were given unfortified egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).

    Other: Control

Interventions

  • Dietary supplementvitamin D-enhanced egg

    In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks. This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D

  • OtherControl

    Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D

06

What researchers measure

Primary outcomes

  1. Serum 25-OH-D

    nmol/L

    Time frame: At baseline and at 12 weeks of intervention

Secondary outcomes

  1. Serum PTH

    pcg/mL

    Time frame: At baseline and at 12 weeks of intervention

Other outcomes

  1. Insulin

    ug/dL

    Time frame: At baseline and at 12 weeks of intervention

  2. Weight

    kg

    Time frame: At baseline and at 12 weeks of intervention

  3. Height

    cm

    Time frame: At baseline and at 12 weeks of intervention

  4. Total Cholesterol

    mg/dL

    Time frame: At baseline and at 12 weeks of intervention

  5. Triglicerids

    mg/dL

    Time frame: At baseline and at 12 weeks of intervention

  6. HDLc

    mg/dL

    Time frame: At baseline and at 12 weeks of intervention

  7. Glucose

    mg/dL

    Time frame: At baseline and at 12 weeks of intervention

07

Study locations

1 site
  • Instituto Nacional de Salud Pública
    Cuernavaca, Morelos 62100, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06096194
Lead sponsor
Instituto Nacional de Salud Publica, Mexico
Responsible party
Mario Flores-Aldana (Mario Flores-Aldana, MD, PhD Nutrition Surveillance, Director, Instituto Nacional de Salud Publica, Mexico) — Principal investigator
First posted
Oct 23, 2023
Start date
Jul 15, 2018
Primary completion
Nov 30, 2018
Completion
Dec 21, 2019
Last update
Oct 23, 2023

Study contacts

Mario E Flores Aldana, PhD
principal investigator · National Institute of Public Health, Mexico

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion